Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Article Title: Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer

doi: 10.1158/1078-0432.CCR-12-2063

Figure Lengend Snippet: PD-1, B7-H1, and B7-DC expression and prognostic significance in cancer patients

Article Snippet: , ( 58 ) , 150 , Paraffin IHC; anti-B7-H1 mAb (5H1) or anti- B7-H1 polyclonal Ab (4059, ProSci) , Membranous PD-L1 expression by melanocytes within the tumors had 3 patterns: no PD-L1; regional expression of PD-L1 on melanocytes colocalized with TILs (most common); and PD-L1 expression absence of TILs , Almost all PD-L1+ tumors were associated with TILs, while only 28% of PD-L1- tumors were associated with TILs; a sample of PD-L1+ tumors with TIL were shown to contain IFNγ, whereas no PD-L1- tumors examined contained IFNγ , PD-L1 was expressed on a proportion (57/150) of various MEL lesions, most commonly in close juxtaposition to TILs; when an inflammatory response to the tumor was detected, it was likely that both the tumor and infiltrating cells were PD-L1+; PD-L1 expression was associated with the superficial spreading and nodular MEL subtypes ( P =0.033) and not with MEL stage , Patients with PD-L1+ metastatic MEL (mMEL) had longer survival than those with PD-L1- metastatic MEL ( P = 0.032); patients with metastatic MEL with TILs had significantly improved survival compared with those without TILs ( P = 0.017).

Techniques: Expressing, Clone Assay, Membrane, Clinical Proteomics, Staining, Comparison, Functional Assay, Western Blot